Search

Your search keyword '"Baglin, T"' showing total 610 results
Start Over Author "Baglin, T"
610 results on '"Baglin, T"'

104. Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of D-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism

Author

Douketis, J., Tosetto, A., Marcucci, M., Baglin, T., Cushman, M., Eichinger, S., Palareti, G., Poli, D., Campbell, T., Tait, R. C., and Iorio, Alfonso

Subjects
Adult, Male, Time Factors, Adolescent, Biological Markers: blood, Fibrin Fibrinogen Degradation Products, Young Adult, Sex Factors, Recurrence, Risk Factors, 80 and over, Humans, Aged, Proportional Hazards Models, Venous Thromboembolism: drug therapy, Age Factors, Anticoagulants, Fibrin Fibrinogen Degradation Products: analysis, Venous Thromboembolism, Middle Aged, Anticoagulants: therapeutic use, Biological Markers, Female, Venous Thromboembolism: blood, Withholding Treatment
Published
2010

116. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism

Author

Church, F. C., Carrell, R. W., Baglin, T. P., Huntington, J. A., and Esmon, C. T.

Abstract

The serine proteases sequentially activated to form a fibrin clot are inhibited primarily by members of the serpin family, which use a unique β-sheet expansion mechanism to trap and destroy their targets. Since the discovery that serpins were a family of serine protease inhibitors there has been controversy as to the role of conformational change in their mechanism. It now is clear that protease inhibition depends entirely on rapid serpin β-sheet expansion after proteolytic attack. The regulatory advantage afforded by the conformational mobility of serpins is demonstrated here by the structures of native and S195A thrombin-complexed heparin cofactor II (HCII). HCII inhibits thrombin, the final protease of the coagulation cascade, in a glycosaminoglycan-dependent manner that involves the release of a sequestered hirudin-like N-terminal tail for interaction with thrombin. The native structure of HCII resembles that of native antithrombin and suggests an alternative mechanism of allosteric activation, whereas the structure of the S195A thrombin–HCII complex defines the molecular basis of allostery. Together, these structures reveal a multistep allosteric mechanism that relies on sequential contraction and expansion of the central β-sheet of HCII.

Published
2002
Full Text
View/download PDF

117. Risk of and prophylaxis for venous thromboembolism in hospital patients

Author

Scurr, J, Baglin, T, Burns, H, Clements, R, Cooke, T, de Swiet, M, Dewar, E, Forbes, C, Frostick, S, Greer, I, Hobbs, R, Jenkins, T, Klein, L, Lanigan, D, Lowe, G, Warwick, D, Wilson, J, and Gr, S

Abstract

Objective: To review the published clinical data on prophylaxis for thromboembolism in order to develop general guidelines to encourage the establishment of local protocols for management. Data sources: Published papers on thromboembolism over the period 1991-1997 were identified by Medline search and/or from the authors' personal literature collections and reviewed. Study selection: A total of 981 studies were identified. Only those papers reporting randomized studies with clearly defined diagnostic methods and clear end-points were included in this review. Data extraction: The available evidence for each specialty was summarized and reviewed by the authors responsible for each specialty, prior to presentation and discussion of their findings within the group. Where a consensus opinion was achieved in a speciality, general guidelines for thromboprophylaxis were summarized. Where a consensus could not be agreed, recommendations for further work were made. Data synthesis: There is evidence to support the preferred use of low-molecular-weight heparins (LMWHs) over unfractionated heparin (UFH) in orthopaedic surgery, major trauma and general surgery. However, the ideal duration of thromboprophylaxis has yet to be defined. The use of once daily subcutaneous administration of LMWH offers major practical advantages and may have significant cost saving implications. Further work is required to investigate the use of thromboprophylaxis in minimal access surgery, trauma, elective lower limb surgery, hip fracture and pregnancy; to compare the efficacy of LMWH and mechanical prophylaxis; and to investigate extended prophylaxis after discharge. Conclusions: There is overwhelming evidence that thromboembolic prophylaxis reduces the incidence of postoperative deep vein thrombosis and pulmonary embolism. Recommendations concerning the management of these patients when stratified into low, moderate and high risk are made with the suggestion that hospitals develop their own guidelines for the treatment of these patients.

Published
1998

122. Pharmacokinetics of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A

Author

DMOSZYNSKA, A., primary, HELLMANN, A., additional, BAGLIN, T., additional, O’SHAUGNESSY, D., additional, TRELINSKI, J., additional, KULICZKOWSKI, K., additional, KLOCZKO, J., additional, HAY, C., additional, ZAWILSKA, K., additional, MAKRIS, M., additional, SHAIKH-ZAIDI, R., additional, GASCOIGNE, E., additional, and DASH, C., additional

Published
2010
Full Text
View/download PDF

126. USE OF A HIGH PURITY FACTOR IX (FIX) CONCENTRATE IN SURGERY

Author

Lee, J.M., primary, Dash, C.H., additional, Chernova, T., additional, Baglin, T., additional, Collins, P., additional, Serban, M., additional, Hay, C., additional, Matysiak, M., additional, Mitchell, V., additional, Plyusch, O., additional, Rusen, L., additional, and Stasyshyn, O., additional

Published
2007
Full Text
View/download PDF

142. A Randomized Trial of Solvent/Detergent and Standard Fresh Frozen Plasma in the Treatment of the Coagulopathy seen during Orthotopic Liver Transplantation

Author

Freeman, J. W., primary, Williamson, L. M., additional, Llewelyn, C., additional, Fisher, N., additional, Allain, J. P., additional, Bellamy, M., additional, Baglin, T. P., additional, Klinc, J., additional, Ala, F. A., additional, Smith, N., additional, Neuberger, J., additional, and Wreghitt, T., additional

Published
1998
Full Text
View/download PDF

148. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data

Author

Marcucci, M., Iorio, A., Douketis, J.D., Eichinger, S., Tosetto, A., Baglin, T., Cushman, M., Palareti, G., Poli, D., Tait, R.C., and Kyrle, P.A.

Abstract

In order to stratify patients with a first unprovoked venous thromboembolism (VTE) according to their recurrence risk and to identify those who would actually benefit from indefinite anticoagulation, three prediction models have been developed so far; none of them has been yet externally validated.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results